RALEIGH, N.C.--(BUSINESS WIRE)--LipoScience, Inc., an in-vitro diagnostic company advancing patient care in cardiovascular, metabolic and other diseases using an innovative and proprietary platform based on Nuclear Magnetic Resonance (NMR) technology, today announced the appointment of Robert Honigberg, M.D. as Chief Medical Officer and Vice President, Medical Affairs. Dr. Honigberg’s responsibilities will include the development and implementation of strategies for clinical trials, partnerships, and publications for both marketed and pipeline products. In addition, he will lead the development of relationships with medical societies, advocacy organizations, academic institutions, health plans, and business partners as LipoScience continues to expand its geographic reach.
“Bob’s expertise in strategy, innovation, and clinical research and measurement will be invaluable as we engage thought leaders, drive publications, and expand managed care coverage decisions,” said Richard O. Brajer, chief executive officer of LipoScience. “His extensive experience in creating and leading clinical and medical affairs organizations will bring immediate and significant benefits to our company.”
Since 2009, Dr. Honigberg served as the Chief Medical Officer, Research & Measurement for URAC, an accreditation commission in Washington, D.C., and as a consultant to a number of start-up companies in diagnostics, devices and healthcare delivery. From 2006-2009, he served as the Chief Medical Officer, Global Medical Affairs and Clinical Strategy, for GE Healthcare, responsible for strategies and operations related to clinical research and trials, protection of patient safety, and medical communication to providers and governments. Dr. Honigberg held the position of Chief Medical Officer and Vice President, Medical and Clinical Affairs at Ethicon Endo-Surgery, a Johnson & Johnson operating company, from 1999-2006. Prior to that, Dr. Honigberg directed clinical trials, medical affairs operations and strategy for Ortho Biotech and Schering-Plough.
“The limitations in using LDL cholesterol as the sole predictor of cardiovascular and metabolic risk are becoming increasingly clear,” said Dr. Honigberg. “LipoScience’s technology platform is changing the way these conditions are assessed and managed and I look forward to playing a meaningful role in the Company’s efforts to drive toward new clinical standards of care.”
Dr. Honigberg is trained as a surgeon and graduated from Duke University with a BA in Economics, obtained his Medical Degree from Northwestern University’s Feinberg School of Medicine, and later an MBA from Northwestern University’s Kellogg School of Management. He undertook his surgical internship and residency at Albert Einstein College of Medicine/Montefiore Medical Center in New York City.
About LipoScience, Inc.
LipoScience, Inc. is an in-vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases using an innovative and proprietary proven platform based on Nuclear Magnetic Resonance (NMR) technology. Our first diagnostic test, the NMR LipoProfile® test measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, six million NMR LipoProfile tests have been ordered by clinicians. For further information on the Company, please visit www.liposcience.com and www.theparticletest.com.